Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Pharmather Hldgs Ltd (CSE: PHRM ) 0.2350 +0.0250 (+11.90%) Streaming Delayed Price Updated: 10:28 AM EST, Nov 13, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 6,500 Open 0.2250 Bid (Size) 0.2200 (47,500) Ask (Size) 0.2350 (54,500) Prev. Close 0.2100 Today's Range 0.2250 - 0.2350 52wk Range 0.1100 - 0.4300 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application Today 8:00 EST From PharmaTher Holdings Ltd. Via GlobeNewswire Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke November 12, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire Performance YTD -30.88% -30.88% 1 Month N/A N/A 3 Month +9.30% +9.30% 6 Month +6.82% +6.82% 1 Year +74.07% +74.07% More News Read More PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application October 23, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Announces Update on FDA New Drug Application for Ketamine September 04, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins August 21, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine) August 19, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine May 15, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine May 10, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine May 01, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine April 18, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine April 16, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder April 02, 2024 From Revive Therapeutics Ltd. Via GlobeNewswire PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia February 21, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine February 12, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Provides Update for Expected FDA Approval of Ketamine January 10, 2024 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine) September 27, 2023 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA September 06, 2023 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics July 18, 2023 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA June 27, 2023 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S. June 20, 2023 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Holdings Provides Corporate Update June 12, 2023 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease May 02, 2023 From PharmaTher Holdings Ltd. Via GlobeNewswire Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech April 03, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease March 29, 2023 From PharmaTher Holdings Ltd. Via GlobeNewswire PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System February 07, 2023 From PharmaTher Holdings Ltd. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
